A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal
A phase 3 trial of Trastuzumab rezetecan, CAPOX, Fluorouracil in colorectal cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
Overview
A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer is a phase 3 interventional study registered as NCT07676162 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 300 participants planned, started 2026-08-28 and due to reach its primary completion in 2029-09. Interventions recorded: SHR-A1811, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab. Conditions listed: Advanced Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
Shares Trastuzumab rezetecan, CAPOX (capecitabine, oxaliplatin), Jiangsu Hengrui Pharmaceuticals, Bevacizumab.
- TrialA Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer
Shares CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU), Bevacizumab, Colorectal cancer.
- TrialBOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Shares CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU), Colorectal cancer.
- TrialA Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil,
Shares CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU), Bevacizumab, Colorectal cancer.
- TrialA Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals.
- TrialA Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals.
- TrialPhase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals.
- TrialSHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Bevacizumab.